Endocrinology: Strategic Modeling and Simulation Services

Certara has broad expertise in endocrine diseases including diabetes, obesity, hypogonadism, and hypoparathyroidism. For example, our scientists have supported diabetes development programs for industry clients, from pre-clinical to Phase 4 commercial strategy. Our consultants have addressed critical issues in trial design, dose selection, extrapolation from animal to human, and development strategy for the major classes of diabetes therapies. We performed projects including population dose-response and PK/PD analyses of efficacy and safety biomarker data, dose selection for renally impaired patients and long-term forecasting of HbA1c levels. Through our work and research we have accumulated extensive knowledge on many classes of drugs, including newer therapies such as glucagon-like peptide-1 (GLP-1) analogs and sodium/glucose cotransporter 2 (SGLT-2).

Disease Areas

  • Type 1 diabetes
  • Type 2 diabetes
  • Hypogonadism
  • Hypoparathyroidism
  • Obesity

Clinical Trial Outcomes Databases

Our extensive knowledge and compilations of public data from the clinical and scientific literature for endocrine diseases provide a ready context for model-based meta-analysis to assess your compound’s performance against competing therapies. Our diabetes clinical trial outcomes database includes safety and efficacy information from trials investigating metformin (MET), sulfonuryleas (SU), thiazoledinediones (TZD), dipeptidyl peptidase-4 (DPP4) inhibitors, GLP-1 analogs, and sodium/glucose cotransporter 2 (SGLT-2) in type-2 diabetes (T2D).

By partnering with Certara Strategic Consulting, you can leverage the power of model-informed drug development technology to get your drug to market faster.